SpaceX is days away from one of the most anticipated initial public offerings in stock market history. The company is expected to price on June 11 and begin trading on June 12 at a valuation Read more…
Market Overview The crypto market capitalisation has risen by 1.3% over the past 24 hours to $2.18 trillion. With no fresh downward momentum, bears are taking profits, while some investors view the situation as a Read more…
EUR/USD recovered just ahead of near term falling channel floor and intraday bias is turned neutral first. Some consolidations could be seen, but risk will stay on the downside as long as 1.1685 resistance holds. Read more…
Further rise could still be seen in USD/JPY. But strong resistance is still expected from 160.71. Break of 159.08 will turn bias back to the downside the extend the corrective pattern from 160.71 with the Read more…
GBP/USD recovered ahead of 1.3300 support as sideway trading continues. Intraday bias remains neutral first. On the downside, break of 1.3300 will target a retest on 1.3158. Firm break there will extend the whole fall Read more…
Intraday bias in USD/CHF is turned neutral first and some consolidations could be seen below 0.7986 temporary top. Risk will stay on the upside as long as 0.7867 minor support holds. Above 0.7986 will resume Read more…
Intraday bias in AUD/USD is turned neutral first with current recovery, and some consolidations could be seen. Risk will stay on the downside as long as 0.7200 resistance holds. Below 0.7022 will resume the fall Read more…
Intraday bias in USD/CAD is turned neutral with current retreat. Further rise is expected as long as 1.3769 support holds.. Above 1.3960 will target 38.2% retracement of 1.4791 to 1.3480 at 1.3981. Decisive break there Read more…
Intraday bias in GBP/JPY is turned neutral with current recovery. Risk will stay mildly on the downside as long as 215.59 resistance holds. Below 212.90 will target 210.43/211.23 support zone. However, firm break of 215.59 Read more…
Monash University’s Andrew R. Snyder, PhD. joins the show to discuss Daraxonrasib, a novel RAS(ON) inhibitor, doubled median overall survival (~13.2 vs ~6.6–6.7 months) versus chemotherapy in a 500‑patient phase 3 trial for previously treated Read more…